SAP30 and cancer: The high expression of SAP30 was associated with reduced drug sensitivity of cancer cells to one drug (Erlotinib) and with increased drug sensitivity of cancer cells to five drugs (Ifosfamide, Nelarabine, Carmustine, Lomustine, and Arsenic trioxide).